OOIR: Observatory of International Research

Papers

(The H4-Index of Future Oncology is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer	121
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma	81
Brain Injury after Cranial Radiotherapy Combined with Immunotherapy for Brain Metastases in Lung Cancer: A Retrospective Study	76
ToPCourT protocol: a phase II trial of Trilaciclib, Pembrolizumab, gemcitabine, and Carboplatin in locally advanced/unresectable or metastatic Triple-negative breast cancer	63
Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design)	62
The relationship between VDR polymorphisms and keratinocyte carcinomas: a systematic review and meta-analysis	57
Immunotherapy for Liposarcoma: Emerging Opportunities and Challenges	57
Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression	57
A Multicenter, Phase Ib/II, Open-Label Study of Tivozanib with Durvalumab in Advanced Hepatocellular Carcinoma (DEDUCTIVE)	57
RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR -mutated NSCLC	54
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis	54
How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported	51
Should One Use the Combination of Abiraterone and Poly(ADP-ribose) Polymerase Inhibitors as First-Line Therapy for all Patients with Metastatic Castration-Resistant Prostate Cancer?	50
Results of a survey study on health professionals’ perceptions of tumor boards in Brazil	40
Diagnosis of chondrosarcoma in a noninvasive way using volatile organic compounds in exhaled breath: a pilot study	39
Sex bias phenomenon in oral cancer: an insight	38
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study	38
In -Class Transition from Bortezomib-Based Therapy to IRd is an Effective Approach in Newly Diagnosed Multiple Myeloma	37
Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites	36
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study	35
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib	34
Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma	33
Cost–effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer	33
Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer	33
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)	33

Molecular preselection of pediatric patients with solid tumors treated with tyrosine kinase inhibitors	32
Trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer: a plain language summary of the DESTINY-Lung02 study	32
Sacituzumab Govitecan: Past, Present and Future of a New Antibody–Drug Conjugate and Future Horizon	32
Barriers and solutions for healthcare professionals to involve patients as partners in oncology research: Project RISE	32
Evaluation of surgical treatment outcomes and development of a prognostic model for patients with small cell lung cancer	31
Crosstalk Between Circrnas and the PI3K/AKT and/or MEK/ERK Signaling Pathways in Digestive Tract Malignancy Progression	31
Correction	31
Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe	31